CN101627026A - 晶体盐酸度洛西汀 - Google Patents

晶体盐酸度洛西汀 Download PDF

Info

Publication number
CN101627026A
CN101627026A CN200780023171A CN200780023171A CN101627026A CN 101627026 A CN101627026 A CN 101627026A CN 200780023171 A CN200780023171 A CN 200780023171A CN 200780023171 A CN200780023171 A CN 200780023171A CN 101627026 A CN101627026 A CN 101627026A
Authority
CN
China
Prior art keywords
duloxetine hydrochloride
organic solvent
crystalline duloxetine
hydrochloride according
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200780023171A
Other languages
English (en)
Chinese (zh)
Inventor
姜维平
贾春荣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHENHUAXI PHARMACEUTICAL CO Ltd CHONGQING
Arrow International Ltd
Original Assignee
SHENHUAXI PHARMACEUTICAL CO Ltd CHONGQING
Arrow International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36803801&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101627026(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SHENHUAXI PHARMACEUTICAL CO Ltd CHONGQING, Arrow International Ltd filed Critical SHENHUAXI PHARMACEUTICAL CO Ltd CHONGQING
Publication of CN101627026A publication Critical patent/CN101627026A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
CN200780023171A 2006-06-23 2007-06-21 晶体盐酸度洛西汀 Pending CN101627026A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0612506.6A GB0612506D0 (en) 2006-06-23 2006-06-23 Crystalline duloxetine hydrochloride
GB0612506.6 2006-06-23

Publications (1)

Publication Number Publication Date
CN101627026A true CN101627026A (zh) 2010-01-13

Family

ID=36803801

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780023171A Pending CN101627026A (zh) 2006-06-23 2007-06-21 晶体盐酸度洛西汀

Country Status (10)

Country Link
US (2) US7799935B2 (enExample)
EP (1) EP2035404A1 (enExample)
JP (1) JP2009541292A (enExample)
CN (1) CN101627026A (enExample)
AU (1) AU2007262801B2 (enExample)
BR (1) BRPI0711954A2 (enExample)
CA (1) CA2656035A1 (enExample)
GB (1) GB0612506D0 (enExample)
NZ (1) NZ573212A (enExample)
WO (1) WO2007148103A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103626735A (zh) * 2012-08-28 2014-03-12 石药集团中奇制药技术（石家庄）有限公司 一种盐酸度洛西汀晶型及其制备方法
CN106265528A (zh) * 2015-05-12 2017-01-04 法德生技药品股份有限公司 制备药物凝集体的方法
CN113603673A (zh) * 2020-11-16 2021-11-05 上海中西三维药业有限公司 一种盐酸度洛西汀的晶型、其制备方法及其应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0612506D0 (en) 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
US8278463B2 (en) 2008-04-04 2012-10-02 Ranbaxy Laboratories Limited Process for the preparation of pure duloxetine hydrochloride
CA2754141A1 (en) 2009-03-13 2010-09-16 Alembic Pharmaceuticals Limited A process for the preparation of duloxetine hydrochloride
JP2016222628A (ja) * 2015-06-03 2016-12-28 株式会社トクヤマ デュロキセチン塩酸塩の製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5362886A (en) 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
WO2005019199A1 (en) 2003-08-25 2005-03-03 Hetero Drugs Limited Amorphous duloxetine hydrochloride
US20050197503A1 (en) 2004-03-05 2005-09-08 Boehringer Ingelheim International Gmbh Process for the preparation of N-alkyl-N-methyl-3-hydroxy-3-(2-thienyl)-propylamines
GB0410470D0 (en) * 2004-05-11 2004-06-16 Cipla Ltd Pharmaceutical compound and polymorphs thereof
WO2006055964A2 (en) 2004-11-19 2006-05-26 Teva Pharmaceutical Industries Ltd. Zolmitriptan crystal forms
US20060116420A1 (en) 2004-11-23 2006-06-01 Ramakrishnan Chidambaram Crystalline forms of 3'-tert-Butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel
EP1730132A2 (en) * 2004-12-23 2006-12-13 Teva Pharmaceutical Industries Ltd Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
US20060270859A1 (en) * 2005-01-27 2006-11-30 Santiago Ini Duloxetine HCl polymorphs
EP1820800A1 (en) * 2006-02-17 2007-08-22 KRKA, tovarna zdravil, d.d., Novo mesto Crystalline forms of duloxetine hydrochloride and processes for their preparation
GB0612506D0 (en) 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103626735A (zh) * 2012-08-28 2014-03-12 石药集团中奇制药技术（石家庄）有限公司 一种盐酸度洛西汀晶型及其制备方法
CN106265528A (zh) * 2015-05-12 2017-01-04 法德生技药品股份有限公司 制备药物凝集体的方法
CN113603673A (zh) * 2020-11-16 2021-11-05 上海中西三维药业有限公司 一种盐酸度洛西汀的晶型、其制备方法及其应用
CN113603673B (zh) * 2020-11-16 2024-08-06 上海中西三维药业有限公司 一种盐酸度洛西汀的晶型、其制备方法及其应用

Also Published As

Publication number Publication date
WO2007148103A1 (en) 2007-12-27
US7799935B2 (en) 2010-09-21
AU2007262801A1 (en) 2007-12-27
BRPI0711954A2 (pt) 2011-12-20
GB0612506D0 (en) 2006-08-02
AU2007262801B2 (en) 2013-01-31
EP2035404A1 (en) 2009-03-18
CA2656035A1 (en) 2007-12-27
US20080021089A1 (en) 2008-01-24
NZ573212A (en) 2012-01-12
US20100331388A1 (en) 2010-12-30
JP2009541292A (ja) 2009-11-26
US8093407B2 (en) 2012-01-10

Similar Documents

Publication Publication Date Title
CN101595099B (zh) 晶体盐酸度洛西汀
JP6511083B2 (ja) ピロール誘導体の結晶
CN101627026A (zh) 晶体盐酸度洛西汀
CN101631783A (zh) 晶体盐酸度洛西汀
ZA200402191B (en) Muscarinic agonists.
WO2010046360A1 (en) Process for the preparation of substantially optically pure repaglinide and precursors thereof
Hu et al. Resolutions of sibutramine with enantiopure tartaric acid derivatives: chiral discrimination mechanism
EA017631B1 (ru) Кристаллическое основание транс-1-((1r,3s)-3-фенил-6-хлороиндан-1-ил)-3,3-диметилпиперазина
CN118324648A (zh) (r)-特布他林苯磺酸盐a晶型和b晶型及其制备方法
US20240239791A1 (en) Processes for the synthesis of valbenazine
EP2177221A1 (en) Process for the preparation of substantially optically pure Repaglinide and precursors thereof
JPS6028825B2 (ja) 新規トリアゾ−ル誘導体の製法
JP2025533955A (ja) （２ｓ，５ｒ）－５－（２－クロロフェニル）－１－（２’－メトキシ－［１，１’－ビフェニル］－４－カルボニル）ピロリジン－２－カルボン酸の多形およびその調製プロセス
MX2007011611A (es) Fumarato de dnt y metodos de preparacion de ellos.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100113